1. Home
  2. SST vs LSTA Comparison

SST vs LSTA Comparison

Compare SST & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

N/A

Current Price

$1.70

Market Cap

19.8M

ML Signal

N/A

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

N/A

Current Price

$1.03

Market Cap

15.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SST
LSTA
Founded
2013
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Misc Health and Biotechnology Services
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.8M
15.9M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
SST
LSTA
Price
$1.70
$1.03
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
55.6K
★ 85.6K
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 20.42
EPS
N/A
★ N/A
Revenue
★ $266,129,000.00
$35,283,868.00
Revenue This Year
N/A
N/A
Revenue Next Year
$21.02
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 56.90
52 Week Low
$1.35
$0.96
52 Week High
$6.05
$5.07

Technical Indicators

Market Signals
Indicator
SST
LSTA
Relative Strength Index (RSI) 30.68 39.67
Support Level $1.68 $0.97
Resistance Level $2.09 $1.28
Average True Range (ATR) 0.19 0.08
MACD -0.03 0.02
Stochastic Oscillator 8.41 36.73

Price Performance

Historical Comparison
SST
LSTA

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: